Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00002274
First received: November 2, 1999
Last updated: October 1, 2007
Last verified: October 2007

November 2, 1999
October 1, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine
An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)

The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV Infections
  • Leukoencephalopathy, Progressive Multifocal
Drug: Didanosine
Not Provided
Abrams DI. Treatment options in zidovudine intolerance or failure. AIDS. 1994 Sep;8 Suppl 3:S3-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Concurrent medications for treatment of complications of AIDS are allowed.
  • Aerosolized pentamidine.
  • Phenytoin, but with caution.
  • Note:
  • Extreme caution should be exercised in the use of didanosine (ddI) in any patient receiving concurrent therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.

Patients must be:

- Not suitable for entry into ddI phase II studies by reason of inclusion or exclusion criteria or by reason of geographic location.

Able to provide signed informed consent (parent/guardian as appropriate). Available for monthly follow-up while taking ddI. Meet required baseline laboratory values within 14 days prior to initial drug dosing.

Note:

  • Extreme caution should be exercised in the use of ddI in any patient receiving concomitant therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.

Caution should also be exercised in a patient having intractable diarrhea or patients following a low-sodium diet. Physicians caring for these patients must perform clinical and laboratory evaluations every 7-10 days for the first 2 months of ddI therapy. Should any adverse effect of any severity be detected during this period of intensive clinical and laboratory monitoring, the physician must call Bristol-Myers Squibb (1-800-662-7999). If the patient continues ddI therapy, Bristol-Myers Squibb will require submission of follow-up and adverse experience report forms every 10 days. Although data are not available to fully assess the risks associated with the use of ddI in high-risk patients (for example, patients with preexisting disorders of body systems known to be adversely affected by ddI, particularly those with history of peripheral neuropathy, pancreatitis, seizure disorder, cardiac abnormalities, gout, and significant elevations of liver function test results), all such patients must have clinical and laboratory evaluations performed every 10 days and results submitted to Bristol-Myers Squibb on the case report forms provided.

Exclusion Criteria

Co-existing Condition:

Patients with any one of the following criteria are excluded:

  • Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT).
  • Taking AZT concomitantly.
  • Acute pancreatitis.
  • Poorly controlled seizure disorder.
  • Taking phenytoin concomitantly.
  • Grade B or greater peripheral neuropathy.

Concurrent Medication:

Excluded:

  • Zidovudine (AZT).

Patients with any one of the following criteria are excluded:

  • Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT).
  • Taking AZT concomitantly.
  • Taking phenytoin concomitantly.
  • Acute pancreatitis.
  • Poorly controlled seizure disorder.
  • Grade B or greater peripheral neuropathy.

Prior Medication:

Excluded within 15 days of study entry:

  • Any antiretroviral except zidovudine (AZT).

Required:

  • Zidovudine (AZT).
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002274
039A, 454-999-002
Not Provided
Not Provided
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP